Incurin Tablets are an effective treatment for the control of estrogen-responsive urinary incontinence in dogs that have undergone surgical removal of the ovaries and uterus (ovariohysterectomy). This medication has been used effectively worldwide for more than 12 years. Incurin Tablets require a prescription from your veterinarian.
Incurin Tablets contain the active ingredient estriol, a natural estrogen, which increases the resting muscle tone of the urethra in female dogs and can be used in the treatment of urinary incontinence due to estrogen depletion. It is given once a day with a starting dose of two tablets for any female dog, regardless of age or weight. The dose of Incurin Tablets is then titrated down over time to the lowest effective dose.
Not for use in humans. Keep this and all drugs out of reach of children and pets. Incurin Tablets are only for use in female dogs that have had surgical removal of the ovaries and uterus. The safety and effectiveness of Incurin Tablets have not been evaluated in dogs less than 1 year of age, intact female dogs, male dogs, dogs used for breeding, or lactating dogs.
Incurin Tablets are used for the treatment and control of urinary incontinence that is estrogen-responsive for female dogs that have undergone ovariohysterectomy (surgical removal of the ovaries and uterus).
Incurin Tablets are available as tablets and require a prescription from your veterinarian.
The dose of Incurin Tablets is not body weight-dependent; all dogs receive an initial dose of 2 tablets orally once per day for a minimum of 14 days. After control of urinary incontinence has been achieved, the lowest effective daily dose should be determined by decreasing the dose in a step-wise manner from 2 tablets, to 1 tablet, then a 1/2 tablet depending on your dog's response. There should be a minimum of 7 days between each dose adjustment. When the lowest dose that controls urinary incontinence is identified, the dose may be decreased further by administering once every two days.
The most common side effects associated with Incurin Tablets treatment under field conditions included loss of appetite, vomiting, excessive water drinking, and swollen vulva.
The safety and effectiveness of Incurin Tablets have not been evaluated in dogs less than 1 year of age, intact female dogs, male dogs, dogs used for breeding, or lactating dogs. Incurin Tablets are contraindicated in dogs showing polyuria (production of excessive amounts of urine) secondary to polydipsia (excessive thirst), or in pregnant dogs.
Contact your veterinarian immediately.
Store at or below 77 °F (25°C) with excursions permitted up to 104°F (40°C).
Dogs should not receive more than 2 mg Incurin per day (2 tablets). If the dog does not respond to 2 mg of Incurin per day, the diagnosis should be re-assessed.
Store at or below 77°F (25°C) with excursions permitted up to 104°F (40°C).